Teva must delist five unlawful inhaler patents in US FDA's Orange Book, judge says
MLex Summary: Teva Pharmaceuticals must correct or delete five patents for asthma inhalers listed in a US Federal Drug Administration registry known as the Orange Book, a New Jersey federal judge...To view the full article, register now.
Already a subscriber? Click here to view full article